Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albemarle Corp. (ALB) vs Align Technology, Inc. (ALGN) Price & Performance

Albemarle Corp.Trade
Align Technology, Inc.Trade

Price performance (Past 24H)

Key statistics

Albemarle Corp. vs Align Technology, Inc. — how do they compare? Albemarle Corp. trades at $128.74 (market cap $15.27B), while Align Technology, Inc. trades at $173.38 (market cap $12.29B). The key difference: Albemarle Corp. is the larger of the two by market cap, and Albemarle Corp. pays a 1.27% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.

ALBALGN
Market Cap
$15.27B$12.29B
Sector
Basic MaterialsHealth
52-Week High
$215.62$197.51
52-Week Low
$72.58$124.88
Enterprise Value
$17.75B$11.30B
Dividend Yield
1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Albemarle Corp.

Albemarle (ALB) trades at $128.29, down 2.23% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company reported strong Q2 2026 results with EPS of $3.75 beating estimates by 17%, driven by improved lithium pricing and specialty chemicals performance. Despite recent profitability challenges with negative net income in 2025, cash flow generation remains healthy at $1.28B from operations.

Analyst consensus leans positive with 42% buy ratings and $184.50 price target representing 44% upside potential. Key risks include lithium price volatility and Q3 margin pressure, while catalysts include sustained demand for energy storage solutions and ongoing balance sheet improvements through debt reduction.

Align Technology, Inc.

ALGN trades at $174.63, down 0.8% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with record revenue and clear aligner volume. Fundamentals show solid profitability with a 68.05% gross margin and 9.99% net income margin, though revenue growth has moderated. Recent news highlights a patent win in China and strategic initiatives following activist investor engagement.

The outlook is mixed: analyst consensus is strongly bullish (73% buy ratings), but technicals and slowing revenue growth pose near-term risks. Investment opportunity lies in international expansion and digital dentistry platform growth, while risks include competitive pressures and execution of new strategic initiatives. The stock's valuation at 30x P/E requires sustained earnings growth to justify.

Returns comparison

Trailing returns across standard periods

About Albemarle Corp.

Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.

Read more on ALB

About Align Technology, Inc.

Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).

Read more on ALGN